Recombinant Hepatocyte Growth Factor Accelerates Cutaneous Wound Healing in Diabetic Mouse Model
Researchers in Japan have discovered that recombinant hepatocyte growth factor (HGF) significantly accelerates cutaneous wound healing in a diabetic mouse model. The study found that topical administration of HGF, along with basic fibroblast growth factor (bFGF), promoted wound closure and re-epithelialization. Notably, HGF treatment enhanced expansion of granulation tissue, stimulated neovascularization, and increased microvessel density, whereas bFGF treatment remained effective even in later stages of wound healing.
Key Takeaways:
- Recombinant HGF significantly accelerates cutaneous wound healing in a diabetic mouse model.
- Topical administration of HGF, in conjunction with bFGF, promotes wound closure and re-epithelialization.
- HGF treatment enhances expansion of granulation tissue and stimulates neovascularization, whereas bFGF treatment remains effective in later stages of wound healing.
- Microvessel density in HGF-treated wounds was higher than in bFGF-treated wounds on day 7 postwounding.
- Matrix metalloproteinases (MMP-2 and MMP-9) activities involved in cell migration, angiogenesis, and extracellular matrix (ECM) remodeling were enhanced by HGF-treatment on day 7.
- DNA synthesis of fibroblasts in granulation tissue was stimulated by bFGF, but not by HGF, suggesting a lesser degree of susceptibility to cutaneous scarring.
- The authors propose that supplement of HGF may be a potential therapeutic approach for the treatment of cutaneous ulcers.
- S. Yoshida and colleagues published the results of their research in Growth Factors, a peer-reviewed journal.
Statistics:
- 22(2):111-119: The journal volume and page range where the study was published, indicating a comprehensive review process.
- 2004: The year of publication, marking the significance of the study in the context of contemporary research.
- 7: The number of days postwounding when the study observed enhanced neovascularization and MMP-2/MMP-9 activities.
- 28: The number of days postwounding when the study observed the extent of granulation tissue in bFGF-treated wounds.
Sources:
- Yoshida, S., et al. (2004) "Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model." Growth Factors, 22(2), 111-119.
- Taylor & Francis Ltd. (Journal publisher).
- Osaka University, Graduate School of Medicine, Course Advanced Med, Division Molecular Regenerat Med (Corresponding author's affiliation).
- Diabetes Week editors (Publication date: 2004).